MedTrace Logo

Postoperative Effects of TAP Block Versus QLB Type 2 Block

NCT03126084 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-11-14

No results posted yet for this study

Summary

This study compares analgesic effectiveness of transversus abdominis plane block and quadratus lumborum block type 2 in open hernia repair surgery. All of the patients will receive routine intravenous analgesic regimen. In addition to that one-third of the patients will receive transversus abdominis plane block, one-third will receive quadratus lumborum block type 2. One-third of the patients will not receive any blocks and will constitute the control group

Conditions

  • Inguinal Hernia
  • Postoperative Pain

Interventions

DRUG

Acetaminophen

1000 mg of intravenous acetaminophen will be administered twice a day

DRUG

0.25% Bupivacaine

20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.

DRUG

0.5% Bupivacaine+Glucose

15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle

DRUG

Tramadol HCl

50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS

PROCEDURE

Inguinal Hernia Repair

Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques

DRUG

0.25% Bupivacaine

10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle

Sponsors & Collaborators

  • Bozyaka Training and Research Hospital

    lead OTHER

Principal Investigators

  • Zeki T TEKGUL, MD · Izmir Bozyaka Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2017-11-11
Completion
2017-11-11

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03126084 on ClinicalTrials.gov